Robert Clarke, PhD
CEO, Kinaset Therapeutics

Robert Clarke, PhD, is a co-founder and Chief Executive Officer of Kinaset Therapeutics since inception in 2020. Under his leadership, Kinaset has advanced their lead best-in-class inhaled pan JAK program to Phase 2 for severe asthma. Dr Clarke has successfully led the company through two rounds of private financing (>$150M) to support clinical development efforts. He was previously Chief Executive Officer at Pulmatrix Inc. (NASDAQ:PULM), a clinical-stage respiratory drug delivery company, from 2012 to 2019 and successfully brought the company public in 2015. Prior to Pulmatrix, Robert began his industry at Alkermes leading R&D teams focused on inhaled and injectable therapeutics. In addition to Kinaset, he is on the Board at Sensory Cloud, previously served on the Board of Spexis AG (SWX:SPEX), and serves on the Environmental Health Engineering Advisory Board at the Johns Hopkins University School of Engineering. Robert holds a Ph.D. in physiology from Johns Hopkins University and completed his post-doctoral training in respiratory biology at Brigham and Women’s Hospital and Harvard University. He has authored more than 100 papers, abstracts, patents, and patent applications.